Dermata Therapeutics (DRMA) Stock: Buy, Sell, or Hold?
DRMA - Dermata Therapeutics, Inc. Common Stock
$1.11
0.01 (0.91%)
▲
5d:
-5.13%
30d:
-14.62%
90d:
-17.16%
HOLD
LOW Confidence
Analysis Updated: Oct 1, 2026 12:00 AM ET
Earnings: Nov 13, 2026
Get Alerted When DRMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: DRMA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: DRMA shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: DRMA is currently trading at $1.11, which is considered slightly low relative to its 30-day fair value range of $1.08 to $1.41.
Technical Outlook: Technically, DRMA is showing sideways momentum. Immediate support is located at $1.06, while resistance sits at $1.25.
Market Sentiment: DRMA scores 78/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $4.00 (+260.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DRMA is showing sideways momentum. Immediate support is located at $1.06, while resistance sits at $1.25.
Market Sentiment: DRMA scores 78/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $4.00 (+260.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$1.08 -
$1.41
Company Quality Score
61/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
94.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (78/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 260.4% below Wall St target ($4.00)
- CAUTION: Bottoming setup, but lagging the sector by 26% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-5.1%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$1.08 -
$1.41
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.06
Resistance Level
$1.25
Current Trend
Sideways
Technical data as of
Oct 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.78
Wall Street Target
$4.00
(+260.4%)
Share & Embed Analysis
Last updated: October 02, 2026 3:04 AM ET
Data refreshes hourly during market hours. Next update: 4:04 AM
Data refreshes hourly during market hours. Next update: 4:04 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DRMA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 63 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$293 | 61 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$128 | 55 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$37 | 57 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
10 analysts |
$70 | 70 BUY |
